Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.02
- Piotroski Score 4.00
- Grade Buy
- Symbol (PULM)
- Company Pulmatrix, Inc.
- Price $6.11
- Changes Percentage (0%)
- Change -$0
- Day Low $5.96
- Day High $6.58
- Year High $8.44
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.42
- Trailing P/E Ratio -0.81
- Forward P/E Ratio -0.81
- P/E Growth -0.81
- Net Income $-14,121,000
Income Statement
Quarterly
Annual
Latest News of PULM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's What Analysts Are Forecasting For Pulmonx Corporation (NASDAQ:LUNG) After Its Third-Quarter Results
Pulmonx Corporation's latest quarterly results showed a 4.0% increase in shares, with revenues meeting expectations and losses per share better than expected. Analysts predict a 23% revenue growth in ...
By Yahoo! Finance | 2 weeks ago -
Airway Therapeutics to trial drug for bronchopulmonary dysplasia in newborn babies
Airway Therapeutics, a US biotech company, will conduct a Phase III trial of zelpultide alfa to prevent bronchopulmonary dysplasia in preterm infants. The drug aims to replace a critical lung protein ...
By Yahoo! Finance | 1 month ago -
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Bayer received $14 million upfront for mosliciguat, a lung-targeted sGC activator. Pulmovant presented promising Phase 1b data at the ERS Congress. The drug showed significant reductions in pulmonary ...
By Yahoo! Finance | 2 months ago
